FindTrial
Sign In

Effect observation of local infiltration with liposomal bupivacaine single dose for postoperative analgesia in patients undergoing thoracoscopic pulmonary resection

Effect observation of local infiltration with liposomal bupivacaine single dose for postoperative analgesia in patients undergoing thoracoscopic pulmonary resection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113516
Enrollment
Unknown
Registered
2025-12-01
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient undergoing uniportal video-assisted thoracoscopic partial pneumoresection?

Interventions

Ropivacaine Group (Group R)??:Ropivacaine
Blank control group(Group C)??:None
Bupivacaine Liposome Group (Group B):Bupivacaine Liposome

Sponsors

Wuhu Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-64 years 2. ASA physical status I-II 3. BMI 18-25 kg/m²;

Exclusion criteria

Exclusion criteria: 1. History of chronic pain 2. Allergy to ropivacaine or bupivacaine 3. Severe heart, lung, liver or kidney dysfunction 4. Central nervous system diseases, mental disorders, or long-term medication use (e.g., Parkinson's disease, alcoholism, sedatives, antidepressants) 5. Poor compliance or communication barriers preventing understanding of VAS scores or PCIA usage;

Design outcomes

Primary

MeasureTime frame
VAS Scale;—

Countries

China

Contacts

Public ContactZou Li

Wuhu Second People's Hospital

897946585@qq.com+86 553 3907271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026